海吉亞醫療(06078.HK)上半年經調整淨利增加65.4%至1.34億元
格隆匯 8 月 25日丨海吉亞醫療(06078.HK)發佈公告，截至2020年6月30日止六個月，集團營業收入同比增加22.8%至人民幣6.323億元；毛利同比增加39.4%至人民幣2.163億元；毛利率由2019年同期的30.1%增加至34.2%；經調整淨利潤同比增加65.4%至人民幣1.34億元；每股基本盈利人民幣0.01元。
集團始終堅持以腫瘤業務為核心的發展戰略，通過直營民營營利性醫院、與第三方醫院合作放療中心、管理集團持有舉辦人權益的民營非營利性醫院，不斷擴大集團的業務規模。集團始終堅持向所有患者提供高品質的醫療服務，始終堅持把提高患者滿意度放在首位。報告期內，集團就診患者數量穩步增加，門診及住院次均費用持續提升，促使2020年上半年集團繼續維持好的發展勢頭，整體收入強勁增長。
報告期內，集團的醫院業務收入為人民幣5.559億元，較上年同期增加24.4%，其中門診醫療服務收入為人民幣1.596億元，較上年同期增長33.3%，住院醫療服務收入為人民幣3.963億元，較上年同期增加21.2%。收入增加得益於成熟醫院的收入持續增長(如成武海吉亞醫院、蘇州滄浪醫院、龍巖市博愛醫院、單縣海吉亞醫院及安丘海吉亞醫院均實現了穩步增長)以及次新醫院的迅猛增長(如重慶海吉亞醫院及菏澤海吉亞醫院收入增長迅速)。截至2020年6月30日止六個月，住院人次為30,382人，較去年同期增加9.2%；門診人次受疫情影響與上年基本持平。集團致力於向病人提供高品質的一站式腫瘤治療服務，使得次均收入持續增長，2020年上半年，住院次均收費為人民幣13,043元，較上年同期上漲11.0%，門診次均收費為人民幣382元，較上年同期增加34.0%。截至2020年6月30日，集團經營或管理十家以腫瘤科為核心的醫院網絡，遍佈中國六個省的七個城市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
